Furlan M, Lämmle B
Central Haematology Laboratory, University Hospital, Bern, Switzerland.
Baillieres Clin Haematol. 1998 Jun;11(2):509-14. doi: 10.1016/s0950-3536(98)80064-4.
Excessive intravascular platelet agglutination in patients with thrombotic thrombocytopenic purpura (TTP) appears to be associated with excessive release from endothelial cells of unusually large von Willebrand factor (vWF) multimers and/or impaired degradation of these multimers by a 'depolymerase' cleaving vWF to smaller, non-agglutinating molecular forms. We studied the activity of a recently described vWF-cleaving protease in four patients, including two brothers, with chronic relapsing TTP. All four patients had lacking or strongly reduced vWF-cleaving protease activity. In another patient with chronic relapsing TTP, the protease deficiency was due to the presence in the patient plasma of an inhibitor that was found to be an IgG. We conclude that constitutional as well as acquired deficiency of vWF-cleaving protease may predispose to clinical manifestation of TTP.
血栓性血小板减少性紫癜(TTP)患者血管内血小板过度凝集似乎与内皮细胞异常大量释放超大血管性血友病因子(vWF)多聚体和/或这些多聚体被一种将vWF切割成较小的、无凝集作用分子形式的“解聚酶”降解受损有关。我们研究了一种最近描述的vWF切割蛋白酶在4例患者(包括一对兄弟)中的活性,这些患者患有慢性复发性TTP。所有4例患者的vWF切割蛋白酶活性均缺乏或显著降低。在另一例慢性复发性TTP患者中,蛋白酶缺乏是由于患者血浆中存在一种被发现为IgG的抑制剂。我们得出结论,vWF切割蛋白酶的先天性及后天性缺乏可能易导致TTP的临床表现。